AcelRx Pharmaceuticals Inc.’s filing revealed that its Chief Executive Officer Angotti Vincent J. acquired Company’s shares for reported $10333.0 on Jun 07. In the deal valued at $0.22 per share,46,400 shares were bought. As a result of this transaction, Angotti Vincent J. now holds 1,016,919 shares worth roughly $ 0.19 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Meanwhile, Credit Suisse downgraded its AcelRx Pharmaceuticals Inc. [ACRX] rating to an Underperform from a a Neutral in a research note published on Tuesday. A number of analysts have revised their coverage, including Credit Suisse’s analysts, who decreased its forecast for the stock in mid November from “an Outperform” to “a Neutral”.
Price Performance Review of ACRX
On Tuesday, AcelRx Pharmaceuticals Inc. [NASDAQ:ACRX] saw its stock fall -8.49% to $0.19. On the same session, the stock had its day’s lowest price of $0.191, but rose to a high of $0.2146. Over the last five days, the stock has lost -3.58%. AcelRx Pharmaceuticals Inc. shares have fallen nearly -65.37% since the year began. Nevertheless, the stocks have fallen -85.30% over the past one year. While a 52-week high of $1.55 was reached on 01/04/22, a 52-week low of $0.16 was recorded on 05/12/22. SMA at 50 days reached $0.2305, while 200 days put it at $0.5371. A total of 1.04 million shares were traded, compared to the trading of 1.1 million shares in the previous session.
Levels Of Support And Resistance For ACRX Stock
The 24-hour chart illustrates a support level at 0.1851, which if violated will result in even more drops to 0.1763. On the upside, there is a resistance level at 0.2087. A further resistance level may holdings at 0.2235. The Relative Strength Index (RSI) on the 14-day chart is 41.44, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0144, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 86.00%. Stochastics %K at 26.00% indicates the stock is a holding.
AcelRx Pharmaceuticals Inc. [ACRX] – Who Are The Largest Shareholders?
In filings from Rock Springs Capital Management L, it is revealed that the company now owns 6,329,202 shares, or roughly 4.30% of the outstanding ACRX shares. In other words, the investor’s shares have risen by 3,300 from its previous 13-F filing of 6325902.0. Additionally, D. E. Shaw & Co. LP increased 2.35% of its stake after which the total value it holdings stand at $864,641, while The Vanguard Group, Inc. reduced -32.22% of its stake to hold $0.78 million in the firm. Over the last quarter, BlackRock Fund Advisors sold -12,960 shares of AcelRx Pharmaceuticals Inc., while Geode Capital Management LLC sold 87,506 shares. At present, Values First Advisors, Inc. is holding 642,515 shares valued at $0.15 million. SSgA Funds Management, Inc. owned 448,731 shares of the company at the time of its most recent 13F filing, worth $0.1 million.
According to FactSet, AcelRx Pharmaceuticals Inc.’s share price will average $4.00 in the next year, based on opinions of analysts polled by the firm. This is up nearly 1804.76 percent from its previous closing price of $0.21. Analysts expect AcelRx Pharmaceuticals Inc. stock to reach the higher price of $4.00, while the lowest price estimate is $4.00. However, 2 analysts have rated ACRX stock as an Overweight in their predictions for 2022.